Pentoxifylline as an adjunct to cyclosporine-based immunosuppression does not improve the outcome of renal transplantation.
The adjunct of PTX to the therapeutic regimen after renal transplantation had no effect on the incidence of ATN, immunologic or infectious complications, or CyA toxicity. Also, patient and graft survival was not affected. The four deaths in the study group can probably not be attributed to PTX therapy. From these data it is concluded that PTX is not able to improve the outcome of renal transplantation.
Königsrainer
A
A
Department of Transplant Surgery, University Hospital Innsbruck, Austria.
Aichberger
C
C
Riedmann
B
B
Steurer
W
W
Ofner
D
D
Margreiter
R
R
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D001379:Azathioprine; D010431:Pentoxifylline